Targeting Mitochondrial Pathways To Reverse Cellular Senescence

Cellular senescence is a central driver of age-related decline, linking metabolic dysfunction, chronic inflammation, and disease progression. Researchers are increasingly exploring whether pharmacological interventions can not only slow, but potentially reverse, aspects of this process by targeting mitochondrial pathways.

Dr. Chang-Hoon Nam, associate professor at the Daegu Gyeongbuk Institute of Science and Technology, is at the forefront of this effort. With research spanning mitochondrial homeostasis and oxidative stress, Nam and colleagues have investigated the anti-obesity drug vutiglabridin as a modulator of cellular senescence.

In this article, Nam explores how senescence reshapes cellular metabolism and circadian biology, the rationale behind repurposing vutiglabridin, and what it will take to translate metabolic–circadian modulators into clinical strategies for aging-associated diseases.

Cellular senescence: A driver of aging and disease

What is cellular senescence, and how is it linked to aging?

 

Cellular senescence represents a permanent exit from the cell cycle triggered by accumulated damage to cellular components. While this process can serve protective roles, its chronic accumulation contributes to tissue dysfunction and disease.

“When cellular components or organelles sustain damage beyond a certain threshold, the cell enters a state in which it ceases to divide,” Nam explained. “This phenomenon, in which the cell cycle is halted, is known as cellular senescence.”

Over time, the buildup of senescent cells has systemic consequences. Repeated cycles of senescence during the aging process contribute to declining organ function, trigger inflammatory responses, and lead to the onset of age-associated diseases.

The role of senescence in aging:

• Cellular senescence is a damage-response mechanism that halts cell proliferation
• Accumulation of senescent cells contributes to organ dysfunction and chronic inflammation
• Senescence is closely linked to age-related diseases, including neurodegeneration

Metabolic reprogramming and circadian disruption in senescent cells

What do we currently know about cellular senescence and its impact on cellular metabolism and the circadian rhythm?

 

Beyond growth arrest, senescent cells undergo profound changes in metabolism and circadian regulation, with implications that extend to organism-level physiology.

“As cellular senescence progresses, the proportion of glycolysis within metabolic processes increases, and consequently, the oxygen consumption rate also tends to rise,” said Nam. These changes reflect altered energy demands and mitochondrial function in aging cells.

At the same time, molecular clock regulation becomes disrupted. The expression of BMAL1, a core circadian gene, declines in senescent cells, leading to lengthened circadian cycles and broader physiological effects.

What we know about senescence-associated dysfunction:

• Senescent cells exhibit metabolic reprogramming, including increased glycolysis
• Oxygen consumption and mitochondrial activity are altered
• Circadian regulators like BMAL1 are downregulated, disrupting biological timing

Repurposing vutiglabridin to alleviate cellular senescence

What inspired you to investigate vutiglabridin as a potential treatment for cellular senescence?

 

Nam and colleagues investigated whether vutiglabridin, a small molecule in clinical trials for its ability to combat obesity by enhancing mitochondrial function, could counteract senescence via its effects on oxidative stress.

A central hypothesis driving the study was that impaired handling of reactive oxygen species (ROS) accelerates senescence. Vutiglabridin may help restore this balance through its impact on paraoxonase 2, an antioxidant enzyme.

“Cellular senescence can develop and progress when the handling of metabolic by-products within the cell—particularly reactive oxygen species—is inadequate,” Nam said.

“The hypothesis was formulated that treating senescent cells with vutiglabridin could alleviate cellular senescence by supporting the function of paraoxonase 2 in regulating oxidative stress,” Nam continued.

Why researchers chose to investigate vutiglabridin as a counteractive to senescence:

• Senescence is linked to ROS accumulation and oxidative stress
• Vutiglabridin modulates paraoxonase 2, a peroxidase enzyme
• Targeting oxidative pathways may reverse or reduce senescence phenotypes

Modeling senescence across cell types

What informed your decision to test vutiglabridin in human dermal fibroblasts?

 

To robustly evaluate vutiglabridin’s effects, Nam’s team examined multiple cellular models of senescence, including primary human dermal fibroblasts (HDFs).

Fibroblasts are particularly useful due to their ability to undergo replicative senescence in vitro through extended culture.

“In the case of fibroblasts, replicative senescence can be induced through prolonged cell culture,” Nam noted. “In contrast, cellular senescence in hepatocytes can be induced by treating them with hydrogen peroxide, a specific ROS.”

By testing across systems, the team aimed to assess whether vutiglabridin’s effects were consistent regardless of how senescence was triggered.

Key findings from the study:

• Chronic treatment of senescent HDFs with vutiglabridin alleviated all investigated markers of cellular senescence and dysfunctional cellular circadian rhythm
• Vutiglabridin prevented alterations of mitochondrial function and structure that occur during the process of cellular senescence
• The findings support the potential development of vutiglabridin against aging-associated diseases

Translational potential of vutiglabridin for combating ageing-related diseases

How close are metabolic‑circadian modulators like vutiglabridin to being used clinically for aging-associated diseases?

While still in early stages, metabolic–circadian modulators such as vutiglabridin are already progressing through clinical pipelines for multiple indications.

“Vutiglabridin is currently being tested in various clinical phases as a candidate drug for the treatment of Parkinson’s disease, obesity, and age-related inflammatory conditions,” Nam said.

These developments suggest that drugs targeting metabolic and oxidative pathways may hold broader relevance for aging-associated diseases, potentially accelerating their adoption in new therapeutic contexts.

Where the field is heading:

• Vutiglabridin is under clinical investigation for neurological and metabolic diseases
• Metabolic–circadian modulators may bridge aging biology and clinical therapeutics

Balancing intervention with the biology of aging

What are some unique factors that need to be considered when researching potential anti-aging therapies?

 

Despite growing interest in anti-aging interventions, Nam emphasized the importance of carefully framing such approaches, particularly given the ongoing debate about whether aging should be treated as a disease.

“Opinions vary as to whether aging can be regarded as a disease,” he says. “If aging is viewed as a natural phenomenon, considerable caution must be exercised when intervening in this process.”

For Nam, targeting cellular senescence represents a measured and biologically grounded strategy. “I believe that intervening in cellular senescence—one of the hallmarks of aging—to mitigate its effects constitutes one such form of cautious intervention.”

 

This content includes text that has been created with the assistance of generative AI and has undergone editorial review before publishing. Technology Networks' AI policy can be found here.